Default company panoramic image

Aciex Respiratory Therapeutics

Redevelop novel form of fluticasone (API in $1 billion Flovent) from BID to QD asthma product via 505(b)2 FDA pathway w/ new 20-year IP life

  • Stage Concept Only
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD

Company Summary

We develop market leading respiratory drugs, combining newly improved compounds with high performance respiratory inhalers to make transformational pulmonary therapies. Our products are cost effective to produce and efficient to distribute. Serves unmet asthmatic & pediatric populations in in US & ROW. Novel single-unit dose improves patient outcomes & overcomes problems of conventional treatments, including contamination, cross-use and loss.


  • Default avatar
    Tom Cavanagh

    Founder of Aciex and President since inception. Responsible for strategic direction of company, fund raising, investor relations and overseeing resources for clinical development projects, intellectual property, product partnering activities, and finance and administration. More than 20 years experience raising money and managing companies. Aciex is the fourth start-up. MBA from Kellogg School of Management. BA from University of Binghamton.

  • Default avatar
    Shahin Sanjar
    Chief Scientific Officer

    25 years pharma experience at GSK & Novartis. Proven track record leading successful research projects. Areas of expertise include respiratory diseases (asthma, COPD, cystic fibrosis, allergy, etc.). Significant contribution to development of brands such as Advair, Serevent, Flovent, Flonase, Xolair, etc. BS in Physiology/Medical Biology from University of St. Andrews and PhD in Pharmacology from University of London


  • Default avatar
    Wilmer Hale
    Default avatar
    Ernst & Young